相关实验视频

Updated: Jun 9, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

平衡瘤免疫疗法和与免疫相关的不良事件:揭示关键调节剂

Jianshang Huang^1,2, Lei Xiong^1,2, Sainan Tang^1,2

¹Laboratory of Molecular Biology, Department of Biochemistry, School of Basic Medical Sciences, Anhui Medical University, No.81, Meishan Rd., Hefei 230032, China.

International journal of molecular sciences

|October 26, 2024

概括

向上皮细胞可以减少癌症免疫疗法的严重副作用. 这种方法旨在降低炎症性肠病的严重程度,而不会影响关键的抗瘤免疫反应.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
胃肠病学胃肠病学

背景情况:

瘤免疫疗法增强了抗癌免疫反应,但可能导致严重的免疫相关不良事件 (irAEs).
瘤细胞创造了一个微环境,抑制了抗瘤免疫力,并可能导致治疗毒性.
目前的irAE治疗往往有缺点,包括免疫疗法的有效性降低或显著的副作用.

研究的目的:

探索用于缓解癌症免疫治疗中的irAEs的新策略.
调查针对皮质屏障功能的潜力,以对irAE进行管理.
确定可以降低irAE严重性的治疗点,同时保持抗瘤免疫力.

主要方法:

关于瘤免疫疗法和irAEs的现有文献的审查.
对炎症性肠病 (IBD) 和其治疗的研究进行分析.
与免疫检查点抑制剂 (ICI) 大肠炎的IBD病变发生的比较.

主要成果:

降低肠上皮质屏障透性的调节显示,有望减少IBD的严重程度.
这种方法保留了关键的免疫媒介,如TNF-α和IFN-γ,对免疫疗法至关重要.
IBD和ICI结肠炎之间的相似性表明它们有着共同的治疗途径.

结论:

向上皮细胞是癌症免疫疗法中管理irAEs的一个有希望的策略.
保持上皮屏障完整性可以提供一种减少irAEs的方法,而不会影响治疗疗效.
未来的研究应该专注于上皮细胞向疗法,以改善癌症治疗结果.

关键词:

CTLA4 CTLA4 在线播放在FKBP8中使用.这是一种ICI结肠炎.在MLCKK中,MLCKK是MLCK.在PD-1/PD-L1中.在IRAEs的基础上.

更多相关视频

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Inflammatory Response

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...